Transcription and Translation

Definition

• Transcription: DNA-templated synthesis of RNA by RNA polymerase, followed in eukaryotes by nuclear processing (capping, polyadenylation, splicing) to produce mature mRNA.
• Translation: ribosome-mediated decoding of mRNA codons into a polypeptide using aminoacyl-tRNAs, with the anticodon pairing antiparallel to the codon.
• Together these constitute gene expression — the step at which genotype becomes phenotype — and each substep is a discrete, druggable, and disease-prone target.

Why it matters clinically

• Antimicrobial selectivity depends on it: nearly every ribosome-active antibiotic exploits 70S versus 80S differences, and rifampin exploits bacterial versus human RNA polymerase. Understanding the target explains both efficacy and off-target toxicity (e.g., linezolid's effect on mitochondrial ribosomes, which resemble the bacterial type).
• Toxinology and poisoning: diphtheria and Shiga toxins and amatoxin all kill by halting expression at defined steps.
• Inherited disease: promoter, splice-site, nonsense, and frameshift mutations produce distinct phenotypes from the same gene — the reason β-thalassemia severity varies and the reason in-frame deletions give Becker rather than Duchenne dystrophy.
• Therapeutics: antisense oligonucleotides that redirect splicing, and mRNA vaccines that supply an exogenous capped, polyadenylated transcript for host ribosomes, are direct clinical applications of this biology.

Epidemiology worth recalling

• Duchenne muscular dystrophy: X-linked, affecting roughly 1 in 3,500–5,000 male births — the prototypical frameshift disease.
• Spinal muscular atrophy: pan-ethnic autosomal recessive splicing/snRNP-assembly disorder, on the order of 1 in 10,000 live births, with carrier frequency in the range of 1 in 40–60. ACOG recommends offering SMA carrier screening to all women considering or already in pregnancy, and SMA sits on the Recommended Uniform Screening Panel for newborns supported by the AAP.
• Hemoglobinopathies: β-thalassemia is among the most common single-gene disorders worldwide, concentrated in Mediterranean, Middle Eastern, South Asian, and Southeast Asian ancestry groups.
• Ribosomopathies (Diamond–Blackfan, Shwachman–Diamond) are individually rare but disproportionately tested.

Transcription — initiation is rate-limiting

• Promoter recognition: eukaryotic TFIID binds the TATA box (~25 bp upstream) and nucleates the pre-initiation complex; prokaryotic sigma factor reads the −10 (Pribnow) and −35 consensus sequences. Promoter escape/clearance, not chain elongation, is the regulated bottleneck.
• Enhancers and silencers: cis-acting, may be thousands of bases away or in introns; loop to the promoter via transcription factors and mediator. Mutations here alter gene dosage without changing coding sequence.
• Three eukaryotic polymerases: RNA pol I makes rRNA (nucleolus), pol II makes mRNA/snRNA, pol III makes tRNA and 5S rRNA. α-amanitin poisons pol II; rifampin poisons the bacterial enzyme; actinomycin D (dactinomycin) blocks both by intercalating DNA.

RNA processing (nucleus, co-transcriptional)

• 5′ 7-methylguanosine cap: added first; required for eIF4E binding and protects from exonucleases.
• 3′ polyadenylation: cleavage after the AAUAAA signal, then poly-A tail; tail length sets cytoplasmic mRNA half-life.
• Splicing: snRNPs (U1–U6) form the spliceosome; U1 binds the 5′ GU donor, branch-point adenosine attacks it to form the lariat, then exons ligate. Alternative splicing lets one gene yield multiple proteins.

Translation — energetics and steps

• tRNA charging: aminoacyl-tRNA synthetase, one per amino acid, hydrolyzes ATP to AMP + PPi (two high-energy bonds) and provides the proofreading step that determines fidelity; the ribosome only checks codon–anticodon pairing.
• Initiation: cap-dependent 40S scanning with eIF2–GTP–Met-tRNA in eukaryotes versus Shine–Dalgarno sequence pairing with 16S rRNA in prokaryotes (formyl-methionine). Initiation is the rate-limiting, hormonally regulated step — eIF2α phosphorylation (heme deficiency, ER/integrated stress response) shuts synthesis off; insulin/mTOR signaling releases 4E-BP and turns it on.
• Elongation: EF-Tu/eEF1A loads the A site (GTP), peptidyl transferase — a ribozyme in the large-subunit rRNA — forms the bond, EF-G/eEF2 translocates (GTP). Net cost ≈ 4 high-energy phosphate equivalents per residue.
• Termination: release factors read UAA/UAG/UGA and hydrolyze the peptidyl-tRNA ester.
• Post-translational: signal peptide + SRP targeting to rough ER, chaperone folding, proteolytic trimming (proinsulin → insulin), glycosylation, hydroxylation, phosphorylation, ubiquitination.

Transcription-level lesions

• Amatoxin poisoning: Amanita phalloides ingestion → RNA pol II inhibition → hepatocyte necrosis after a deceptive 6–24 hour asymptomatic latency, then GI phase, then fulminant hepatic failure. AASLD acute liver failure guidance emphasizes early transfer to a transplant center; care is supportive.
• Promoter/enhancer mutations: β-thalassemia can arise from promoter or splice-site (not only nonsense) mutations, giving reduced β-globin output with microcytic anemia and elevated HbF/HbA2.

Splicing failures

• Anti-Sm and anti-U1 RNP antibodies: autoantibodies against spliceosomal snRNPs — anti-Smith is highly specific for SLE, anti-U1 RNP for mixed connective tissue disease.
• Spinal muscular atrophy: SMN1 loss impairs snRNP assembly → anterior horn cell death, hypotonic infant with tongue fasciculations and preserved cognition. Antisense oligonucleotide (nusinersen) redirects SMN2 splicing; ACOG recommends offering SMA and cystic fibrosis carrier screening to all women considering pregnancy or already pregnant, and SMA is on the recommended uniform newborn screening panel endorsed by the AAP.

Translation-machinery lesions

• Diphtheria toxin and Pseudomonas exotoxin A: ADP-ribosylate eEF2 → pseudomembranous pharyngitis, bull neck, myocarditis. CDC management is diphtheria antitoxin plus an antibiotic (macrolide such as erythromycin, or penicillin) with isolation and contact vaccination.
• Shiga/Shiga-like toxin: cleaves an adenine from 28S rRNA of the 60S subunit → bloody diarrhea and HUS; antibiotics and antimotility agents are avoided because they increase HUS risk (IDSA infectious diarrhea guideline).
• Ribosomopathies: Diamond–Blackfan anemia (ribosomal protein genes) — macrocytic anemia, triphalangeal thumbs, craniofacial anomalies; Shwachman–Diamond — neutropenia plus exocrine pancreatic insufficiency.
• Mitochondrial tRNA mutations: MELAS and MERRF; maternal inheritance with heteroplasmy and variable expressivity, lactic acidosis, ragged red fibers.

Post-translational failures

• I-cell disease: absent mannose-6-phosphate tag → lysosomal enzymes secreted; coarse facies, corneal clouding, gingival hyperplasia, early death.
• Osteogenesis imperfecta: defective collagen triple-helix processing → fractures, blue sclerae, hearing loss.

• Fidelity lives in the synthetase, not the ribosome: aminoacyl-tRNA synthetase proofreads the amino acid–tRNA pair; if it mischarges, the wrong residue is inserted because the ribosome only verifies codon–anticodon pairing. Classic single-best-answer for "where is the error checked?"
• Rate-limiting step of both processes is initiation: promoter escape in transcription, eIF2/eIF4E-dependent initiation in translation. Heme deficiency and ER stress phosphorylate eIF2α and shut translation down — the mechanistic link between iron/heme status and globin synthesis.
• Toxin-to-target matching is tested every cycle: diphtheria and Pseudomonas exotoxin A → eEF2 by ADP-ribosylation; Shiga toxin → 60S/28S rRNA; puromycin → premature chain release; α-amanitin → RNA pol II; rifampin → bacterial RNA polymerase.
• 50S vs 30S is the recurring antibiotic distractor: macrolides, clindamycin, chloramphenicol and linezolid act at the 50S; aminoglycosides and tetracyclines at the 30S. "Buy AT 30, CCEL(L) at 50" — misassigning linezolid or clindamycin is the most common miss.
• Anti-Smith = spliceosomal snRNP = SLE-specific; anti-U1 RNP points to mixed connective tissue disease. The buzzword is the snRNP, not the DNA.
• Nonsense vs frameshift vs splice-site: a nonsense mutation creates a premature stop and triggers nonsense-mediated decay; a splice-site mutation retains an intron or skips an exon (β-thalassemia); frameshifts are usually most damaging. In-frame deletions give the milder allelic disease — Becker rather than Duchenne dystrophy.
• Wobble is the third position: silent mutations cluster there because of degeneracy; do not attribute silent changes to the first or second base.
• Energy accounting: ~4 high-energy phosphate equivalents per peptide bond (2 from ATP→AMP during charging, 2 GTP in elongation) — a favorite quantitative stem.
• Macrocytic anemia plus thumb anomaly should trigger Diamond–Blackfan anemia (a ribosomopathy), not a nutritional deficiency.

• DNA → RNA → Protein follows the central dogma; transcription occurs in nucleus, translation in cytoplasm
• RNA polymerase II transcribes mRNA in eukaryotes; prokaryotes use single RNA polymerase
• Ribosomes (70S prokaryotic, 80S eukaryotic) read mRNA in 5'→3' direction via tRNA anticodon-codon pairing
• Three stop codons (UAA, UAG, UGA) terminate translation; AUG is start codon (codes for methionine)
• Wobble base pairing at 3rd codon position allows one tRNA to recognize multiple codons

• Student memorizing genetic code tables facing questions on codon usage and wobble pairing
• Drug mechanism question: rifampicin blocks prokaryotic transcription; diphtheria toxin inhibits EF-2 in eukaryotic translation
• Genetic disorder: Duchenne muscular dystrophy from frameshift mutation causing premature stop codon

1. 1.Codon direction confusion: mRNA read 5'→3', anticodon pairs in antiparallel (3'→5'); students reverse this
2. 2.Ribosome subunit assembly: 40S + 60S = 80S (eukaryotic); 30S + 50S = 70S (prokaryotic); mixing these up is common
3. 3.Transcription location error: Nuclear transcription produces pre-mRNA (with introns); forgetting that splicing occurs before translation reaches cytoplasm

Not applicable (molecular biology topic). However, for clinical applications

• Antibiotics targeting translation: Preferred for gram-positive/negative bacteria (prokaryotic ribosomes only)
• Cancer chemotherapy: Targeting rapidly dividing cells with high translation rates
• Genetic counseling: Frame-shift mutations warrant discussion of severity vs. missense mutations

EXAM TIPS